Citation: Jp. Rindone et al., A COMPARISON OF FLUVASTATIN 40 MG EVERY OTHER DAY VERSUS 20 MG EVERY DAY IN PATIENTS WITH HYPERCHOLESTEROLEMIA, Pharmacotherapy, 18(4), 1998, pp. 836-839
Citation: Jp. Rindone et G. Arriola, CONVERSION FROM FLUVASTATIN TO SIMVASTATIN THERAPY AT A DOSE RATIO OF8 TO 1 - EFFECT ON SERUM-LIPID LEVELS AND COST, Clinical therapeutics, 20(2), 1998, pp. 340-346
Citation: Jp. Rindone et al., EFFECT OF HOME BLOOD-GLUCOSE MONITORING ON THE MANAGEMENT OF PATIENTSWITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS IN THE PRIMARY-CARE SETTING, American journal of managed care, 3(9), 1997, pp. 1335-1338
Citation: Jp. Rindone et Og. Arriola, EXPERIENCE WITH CRYSTALLINE NIACIN AS THE PREFERRED DRUG FOR DYSLIPIDEMIA IN A SPECIALTY CLINIC, Pharmacotherapy, 17(6), 1997, pp. 1296-1299
Citation: Ma. Ford et al., LACK OF EFFECT OF FLUOXETINE ON THE HYPOPROTHROMBINEMIC RESPONSE OF WARFARIN, Journal of clinical psychopharmacology, 17(2), 1997, pp. 110-112
Citation: Jp. Rindone et al., CHANGES IN SERUM-LIPIDS WHEN FLUVASTATIN IS SUBSTITUTED FOR LOVASTATIN IN THE SAME DOSES, The American journal of cardiology, 80(3), 1997, pp. 348
Citation: Jp. Rindone et G. Bryan, PHENYTOIN TOXICITY ASSOCIATED WITH TICLOPIDINE ADMINISTRATION, Archives of internal medicine, 156(10), 1996, pp. 1113-1113
Citation: Jp. Rindone et al., EFFECT OF LOVASTATIN ADMINISTERED EVERY OTHER DAY ON SERUM LOW-DENSITY-LIPOPROTEIN CHOLESTEROL GREATER-THAN-160 MG DL/, The American journal of cardiology, 76(4), 1995, pp. 312-313